TABLE 2.

Activities of selected agents against clinical Stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or TMP-SMZ stratified according to infection type, acquisition setting, and geographic origin^a

Parameter and drug	MIC (mg/liter)			% susceptible
	50%	90%	Range
Infection type
Pneumonia (n = 32)
Ceftazidime	64	>128	1 to >128	15.6
Ceftazidime-avibactamb	64	128	0.125 to >128	18.2
Chloramphenicol	16	>64	2 to >64	28.1
Delafloxacin	8	16	0.5 to 16
Eravacycline	2	8	0.5 to 8
Levofloxacin	8	>16	0.25 to >16	28.1
Minocycline	2	4	0.125 to 8	93.8
Moxifloxacin	4	8	0.125 to 16
Omadacycline	8	32	0.5 to 64
Polymyxin Bc	0.25	>8	0.06 to >8	75.0
Tigecyclined	1	8	0.125 to 8	71.9
TMP-SMZe	8	>8	0.03 to >8	37.5
Nonpneumonia (n = 9)
Ceftazidime	64		1 to >128	22.2
Ceftazidime-avibactamb	64		1 to >128	22.2
Chloramphenicol	32		8 to >64	11.1
Delafloxacin	8		1 to 32
Eravacycline	2		0.5 to 16
Levofloxacin	8		0.5 to >16	33.3
Minocycline	2		1 to 8	88.8
Moxifloxacin	4		0.5 to 16
Omadacycline	16		2 to >64
Polymyxin Bc	2		0.03 to >8	66.7
Tigecyclined	1		0.125 to >8	77.7
TMP-SMZe	8		1 to >8	33.3
Acquisition setting
Community (n = 17)
Ceftazidime	64	>128	1 to >128	23.5
Ceftazidime-avibactamb	64	>128	0.125 to >128	29.4
Chloramphenicol	16	64	2 to 64	35.3
Delafloxacin	8	16	1 to 16
Eravacycline	2	8	0.5 to 16
Levofloxacin	4	16	0.5 to >16	35.3
Minocycline	2	8	0.5 to 8	82.4
Moxifloxacin	2	8	0.25 to 16
Omadacycline	8	64	0.5 to >64
Polymyxin Bc	0.25	4	0.03 to 8	82.3
Tigecyclined	1	8	0.125 to >8	82.3
TMP-SMZe	8	>8	0.25 to >8	35.3
Nosocomial (n = 16)
Ceftazidime	64	>128	1 to >128	12.5
Ceftazidime-avibactamb	64	128	1 to >128	12.5
Chloramphenicol	32	>64	8 to >64	6.3
Delafloxacin	8	16	0.5 to 32
Eravacycline	2	8	1 to 8
Levofloxacin	16	>16	0.25 to >16	18.8
Minocycline	2	4	0.125 to 4	100
Moxifloxacin	4	16	0.125 to 16
Omadacycline	16	64	2 to 64
Polymyxin Bc	0.5	>8	0.06 to >8	68.8
Tigecyclined	2	8	0.5 to 8	62.5
TMP-SMZe	8	>8	0.5 to >8	37.5
Geographic origin
U.S. (n = 17)
Ceftazidime	128	>128	1 to >128	17.6
Ceftazidime-avibactamb	64	128	0.125 to >128	23.5
Chloramphenicol	16	32	2 to 64	35.3
Delafloxacin	8	16	0.5 to 16
Eravacycline	2	8	0.5 to 8
Levofloxacin	8	>16	0.25 to >16	35.3
Minocycline	2	8	0.5 to 8	88.2
Moxifloxacin	4	16	0.125 to 16
Omadacycline	8	64	1 to 64
Polymyxin Bc	0.5	>8	0.03 to >8	70.6
Tigecyclined	1	8	0.25 to 8	76.5
TMP-SMZe	8	>8	0.03 to >8	29.4
Non-U.S. (n = 24)
Ceftazidime	64	>128	1 to >128	16.7
Ceftazidime-avibactamb	64	>128	1 to >128	16.7
Chloramphenicol	32	>64	4 to >64	16.7
Delafloxacin	8	16	1 to 32
Eravacycline	2	8	0.5 to 16
Levofloxacin	8	>16	0.5 to >16	25.0
Minocycline	2	4	0.125 to 8	95.8
Moxifloxacin	4	8	0.5 to 16
Omadacycline	16	32	0.5 to >64
Polymyxin Bc	0.5	>8	0.06 to >8	75.0
Tigecyclined	1	8	0.125 to >8	70.8
TMP-SMZe	8	>8	0.25 to >8	41.7

^aNo statistically significant differences in MIC distribution were present for any agent based on infection type, acquisition setting, or location using the Mann-Whitney U test.

^bSusceptibility interpretations based on CLSI-approved breakpoints for ceftazidime alone.

^cBased on CLSI breakpoints for Pseudomonas aeruginosa.

^dBased on FDA breakpoints for Enterobacteriaceae.

^eReflects MIC of trimethoprim component only.